Iclusig 30 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Ponatinib
AP24534-14-203
Phase 2 small_molecule active
Quick answer
Iclusig 30 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Ponatinib for Chronic Phase Chronic Myeloid Leukemia is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Chronic Phase Chronic Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active